.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The Evolution of Chimeric Antigen Receptor T Cell Therapy

EP. 1: Clinical Trial Data for Respective CAR T-Cell Therapies

January 8th 2019

EP. 2: A Historic Perspective on High-Risk Lymphoma Management

January 8th 2019

EP. 3: CAR T-Cell Therapy: Real-World Applications

January 8th 2019

EP. 4: Optimizing the Use of CAR T-Cell Therapy in Lymphoma

January 8th 2019

EP. 5: Potential Use of CAR T-Cell Therapy Earlier in Sequencing

January 8th 2019

EP. 6: Tisagenlecleucel for Pediatric and Young Adult ALL

January 8th 2019

EP. 7: Practical Applications of CAR T-Cell Therapy in ALL

January 8th 2019

EP. 8: Considering Differences Among CAR T-Cell Therapies

January 8th 2019

EP. 9: CAR T-Cell Therapy's Role in the ALL Treatment Paradigm

January 8th 2019

EP. 10: CAR T-Cell Therapy in Adult Acute Lymphoblastic Leukemia

January 8th 2019

EP. 11: CAR T-Cell Therapy: Understanding Indicators of Response

January 8th 2019

EP. 12: Outpatient Administration Potential of CAR T-Cell Therapy

January 8th 2019

EP. 13: Is the Community Setting Ready for CAR T-Cell Therapy?

January 8th 2019

EP. 14: CAR T-Cell Therapy in Other Disease Settings and Beyond

January 8th 2019